DGS Capital Management LLC Has $338,000 Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

DGS Capital Management LLC raised its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 12.6% in the fourth quarter, HoldingsChannel.com reports. The firm owned 15,340 shares of the company’s stock after purchasing an additional 1,713 shares during the quarter. DGS Capital Management LLC’s holdings in Teva Pharmaceutical Industries were worth $338,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Coronation Fund Managers Ltd. acquired a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at about $1,334,000. American Century Companies Inc. lifted its stake in Teva Pharmaceutical Industries by 12.9% in the second quarter. American Century Companies Inc. now owns 175,178 shares of the company’s stock valued at $2,847,000 after buying an additional 20,026 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Teva Pharmaceutical Industries by 23.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,466,704 shares of the company’s stock worth $23,834,000 after buying an additional 274,891 shares in the last quarter. Vanguard Personalized Indexing Management LLC increased its stake in shares of Teva Pharmaceutical Industries by 26.7% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 27,643 shares of the company’s stock valued at $449,000 after acquiring an additional 5,831 shares in the last quarter. Finally, Thrivent Financial for Lutherans lifted its position in shares of Teva Pharmaceutical Industries by 44.1% during the 2nd quarter. Thrivent Financial for Lutherans now owns 184,293 shares of the company’s stock valued at $2,995,000 after acquiring an additional 56,388 shares during the period. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA opened at $21.74 on Friday. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57. Teva Pharmaceutical Industries Limited has a 12-month low of $11.48 and a 12-month high of $22.80. The company has a market cap of $24.62 billion, a PE ratio of -25.57, a price-to-earnings-growth ratio of 1.11 and a beta of 0.73. The stock has a 50-day moving average price of $19.74 and a 200-day moving average price of $18.40.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. JPMorgan Chase & Co. lifted their price target on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, October 21st. StockNews.com downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Piper Sandler upped their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, January 17th. Barclays lifted their target price on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the company an “overweight” rating in a research report on Wednesday, December 18th. Finally, UBS Group boosted their price target on shares of Teva Pharmaceutical Industries from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Thursday. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.63.

Insider Transactions at Teva Pharmaceutical Industries

In related news, Director Roberto Mignone sold 286,000 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, December 20th. The shares were sold at an average price of $22.01, for a total value of $6,294,860.00. Following the transaction, the director now owns 695,000 shares in the company, valued at $15,296,950. This trade represents a 29.15 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Christine Fox sold 19,388 shares of the business’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the sale, the executive vice president now directly owns 44,104 shares of the company’s stock, valued at approximately $744,034.48. This trade represents a 30.54 % decrease in their position. The disclosure for this sale can be found here. 0.55% of the stock is currently owned by insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.